Treatment of alzheimer's disease with vascular progenitor-derived exosomes enriched with micrornas or thioredoxin
AssigneeUniversity of Maryland, Baltimore
InventorsPeixin YANG, Wei-Bin SHEN
Life of this patent
Estimating the term…
Abstract
Methods for treating and/or preventing Alzheimer's disease via administration of thioredoxin-1 (Trx1) mRNA- or miR-551b miR-NA-containing exosomes derived from Flk-1+ vascular endothelial progenitor cells are reported. Further, wherein the subject carries the APOE E4 risk factor gene; wherein the subject also has mild cognitive impairment (MCI); and wherein the Flk-1+ exosomes are derived from vascular endothelial progenitor cells or the exosomes are derived from neural stem cells.
Claims19
A method of treating and/or preventing Alzheimer's disease (AD) and AD-related dementia, comprising administering a therapeutically-effective amount of exosomes to a subject in need thereof, wherein the exosomes contain a therapeutic agent for AD and/or AD-related dementia.
A method of delaying onset of symptoms of AD and AD-related dementia, comprising administering a therapeutically-effective amount of exosomes to a subject in need thereof, wherein the exosomes contain a therapeutic agent for AD and/or AD-related dementia.
A method of suppressing ASK1 activity in the brain of a subject, comprising administering a therapeutically-effective amount of exosomes to a subject in need thereof, wherein the exosomes contain a therapeutic agent that inhibits ASK1 gene transcription, inhibits ASK1 mRNA translation, or inhibits ASK1 protein activity.
19-36. (canceled)
Dependencies are inferred from the claim text.